United States Patent 4,962,115: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 4,962,115, titled "Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives," is a patent that describes a class of compounds useful for stimulating the motility of the gastrointestinal system. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Patent Overview
Publication Number and Authority
The patent, US 4,962,115 A, was issued by the United States Patent and Trademark Office (USPTO) and is categorized under the authority of the United States[4].
Prior Art and Legal Status
The patent was filed on June 25, 1987, and granted on October 9, 1990. As of the current date, the patent has expired, marking the end of its lifetime[4].
Scope of the Invention
Description of the Compounds
The patent describes novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives. These compounds are distinguished by their substitution in the 3-position of the piperidine ring, which sets them apart from prior art compounds. The invention includes the pharmaceutically acceptable acid addition salts, stereochemically isomeric forms, and pharmaceutically acceptable quaternary ammonium salts of these derivatives[4].
Pharmacological Properties
The compounds are specifically useful as stimulators of the motility of the gastrointestinal system. This makes them potential therapeutic agents for treating conditions related to gastrointestinal motility disorders[4].
Claims of the Patent
Independent and Dependent Claims
The patent includes several claims that define the scope of the invention. The independent claims describe the general structure of the N-(3-hydroxy-4-piperidinyl)benzamide derivatives, while the dependent claims specify various aspects such as the substitution patterns, stereochemical forms, and pharmaceutical salts[4].
Claim Structure
For example, Claim 1 might describe the general formula of the compounds, while subsequent claims might detail specific substituents, such as the type of hydroxy group or the configuration of the piperidine ring.
Classification and Categorization
International Patent Classification (IPC)
The patent is classified under various IPC categories, including C07D213/60, C07D213/72, and C07D213/75. These classifications indicate that the compounds fall under the category of heterocyclic compounds containing six-membered rings with specific nitrogen and double bond configurations[4].
Patent Landscape
Related Patents and Prior Art
The patent landscape surrounding US 4,962,115 includes other patents related to piperidinyl benzamides. For instance, prior art patents describe similar compounds useful for treating gastric ulcers, psychic disorders, and migraine, but these differ in their substitution patterns and pharmacological properties[4].
Global Patent System
To understand the global reach of this invention, one would need to search international patent databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO)[1].
Search and Analysis Tools
USPTO Resources
Tools like the USPTO's Patent Public Search, Global Dossier, and the Common Citation Document (CCD) can be used to search for related patents and analyze the citation data to understand the broader patent landscape[1].
Patent Claims Research Dataset
The USPTO's Patent Claims Research Dataset can provide detailed information on claims from U.S. patents, including those related to the chemical and pharmaceutical fields. This dataset can help in analyzing the scope and trends of patent claims in this area[3].
Impact and Applications
Therapeutic Use
The compounds described in US 4,962,115 have potential therapeutic applications in treating gastrointestinal motility disorders. This makes the patent significant in the field of pharmaceuticals, particularly in the development of new therapeutic options.
Economic and Research Implications
The expiration of the patent means that the compounds and their uses are now in the public domain, which can stimulate further research and development by other entities. This can lead to new innovations and potentially more effective treatments.
Key Takeaways
- Patent Scope: The patent describes novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives with specific pharmacological properties.
- Claims: The patent includes independent and dependent claims defining the structure and pharmaceutical forms of the compounds.
- Classification: The patent is classified under IPC categories related to heterocyclic compounds.
- Patent Landscape: The landscape includes related patents and prior art, with tools like USPTO's Patent Public Search and Global Dossier aiding in analysis.
- Impact: The patent has potential therapeutic applications and, now expired, is open for further research and development.
FAQs
What is the main subject of United States Patent 4,962,115?
The main subject of US 4,962,115 is the description of novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives and their use as stimulators of gastrointestinal motility.
What is the current legal status of the patent?
The patent has expired, marking the end of its lifetime.
How can one search for related patents?
One can use tools like the USPTO's Patent Public Search, Global Dossier, and the Common Citation Document (CCD) to search for related patents.
What are the potential therapeutic applications of the compounds described in the patent?
The compounds have potential therapeutic applications in treating gastrointestinal motility disorders.
Where can one find detailed information on claims from U.S. patents?
The USPTO's Patent Claims Research Dataset provides detailed information on claims from U.S. patents.
What are the implications of the patent's expiration?
The expiration of the patent means that the compounds and their uses are now in the public domain, which can stimulate further research and development by other entities.
